Cited by 303Epigenetics and DNA MethylationChromatin Remodeling and CancerCancer Cells and Metastasis

The DOI matches its Crossref record; 96 of the 96 references it cites were found in a registry or an index.

Poised epigenetic states and acquired drug resistance in cancer

Brown, Robert, Curry, Edward, Magnani, Luca, Wilhelm-Benartzi, Charlotte S., Borley, Jane·2014·Nature Reviews Cancer

Open this paper in CoChat — free account

Abstract

Epigenetic events, which are somatically inherited through cell division, are potential drivers of acquired drug resistance in cancer. The high rate of epigenetic change in tumours generates diversity in gene expression patterns that can rapidly evolve through drug selection during treatment, leading to the development of acquired resistance. This will potentially confound stratified chemotherapy decisions that are solely based on mutation biomarkers. Poised epigenetic states in tumour cells may drive multistep epigenetic fixation of gene expression during the acquisition of drug resistance, which has implications for clinical strategies to prevent the emergence of drug resistance.

Integrity signals

Registry

Crossref · 10.1038/nrc3819

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Epigenetic Regulations of GABAergic Neurotransmission: Relevance for Neurological Disorders and Epigenetic Therapy
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,951
Cancer Genome Landscapes
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
Bernstein, B. E., Mikkelsen, T. S., Xie, X., Kamal, M., Huebert, D. J., Cuff, J., Fry, B., Meissner, A., Wernig, M., Plath, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.02.041 · Cited by 5,361
Cancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations
Sharma, S. V., Lee, D. Y., Li, B., Quinlan, M. P., Takahashi, F., Maheswaran, S., McDermott, U., Azizian, N., Zou, L., Fischbach, M. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.027 · Cited by 2,770
The polycomb group protein EZH2 is involved in progression of prostate cancer
Varambally, S., Dhanasekaran, S. M., Zhou, M., Barrette, T. R., Kumar-Sinha, C., Sanda, M. G., Ghosh, D., Pienta, K. J., Sewalt, R. G. A. B., Otte, A. P., et al. (2002) · Nature · doi:10.1038/nature01075 · Cited by 2,717
Tumour heterogeneity and cancer cell plasticity
Meacham, C. E., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12624 · Cited by 2,526
Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing
Ding, L., Ley, T. J., Larson, D. E., Miller, C. A., Koboldt, D. C., Welch, J. S., Ritchey, J. K., Young, M. A., Lamprecht, T., McLellan, M. D., et al. (2012) · Nature · doi:10.1038/nature10738 · Cited by 1,993

Flagged first, then by citations

Show all 96 references

Sorted by citations

Items 201–300 of 303

Advances in ovarian tumor stem cells and therapy
Chen, B., & Liu, J. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01385-8 · Cited by 9
A conserved expression signature predicts growth rate and reveals cell & lineage-specific differences
Jiang, Z., Generoso, S., Badia, M., Payer, B., & Carey, L. B. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009582 · Cited by 10
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancer
Hua, Y., Duan, N., Sun, C., Yang, F., Tian, M., Sun, Y., Zhao, S., Gong, J., Liu, Q., Huang, X., et al. (2025) · eLife · doi:10.7554/elife.103953.3 · Cited by 15
The Emerging Landscapes of Long Noncoding RNA in Thyroid Carcinoma: Biological Functions and Clinical Significance
Zhu, J., Liu, C., Wang, D., Cao, X., Wang, S., Liu, Y., Wang, J., Li, P., & He, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.706011 · Cited by 8
Multiscale modeling of drug resistance in glioblastoma with gene mutations and angiogenesis
Yang, H., Lin, H., & Sun, X. (2023) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2023.10.037 · Cited by 8
Rewiring the solid tumor epigenome for cancer therapy
Braun, C. J., & Hemann, M. T. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1212663 · Cited by 8
Molecular epigenetic targets for liver diseases: current challenges and future prospects
Zeidler, R. B., Freitas, B., Bader, A., & Giri, S. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.07.008 · Cited by 8
Bridging Tumorigenesis and Therapy Resistance With a Non-Darwinian and Non-Lamarckian Mechanism of Adaptive Evolution
Catania, F., Újvári, B., Roche, B., Capp, J., & Frédéric Thomas, A. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.732081 · Cited by 11
Natural Agents-Mediated Targeting of Histone Deacetylases
Farooqı, A. A., Naqvi, S. K., Aras, A., Yanar, O., Tabassum, S., Ahmad, M. S., Mansoor, Q., Ashry, M. S. E., Ismail, M., Naoum, G. E., et al. (2017) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-017-0488-0 · Cited by 8
Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumors: Small Steps Toward Personalized Medicine?
Ravegnini, G., & Ricci, R. (2019) · Epigenetics Insights · doi:10.1177/2516865719842534 · Cited by 8
Artificial Intelligence and Machine Learning in Precision Health: An Overview of Methods, Challenges, and Future Directions
Bennett, R., Hemmati, M., Ramesh, R., & Razzaghi, T. (2024) · Springer optimization and its applications · doi:10.1007/978-3-031-74006-0_2 · Cited by 8
Single-cell characterization of step-wise acquisition of carboplatin resistance in ovarian cancer
Wenzel, A. T., Champa, D., Venkatesh, H., Sun, S., Tsai, C., Mesirov, J. P., Bui, J. D., Howell, S. B., & Harismendy, O. (2022) · npj Systems Biology and Applications · doi:10.1038/s41540-022-00230-z · Cited by 10
Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth
Chava, S., Wajapeyee, N., Malvi, P., & Gupta, R. (2022) · iScience · doi:10.1016/j.isci.2022.104752 · Cited by 7
A systematic literature review assessing if genetic biomarkers are predictors for platinum-based chemotherapy response in ovarian cancer patients
Phillips-Chavez, C., Watson, M., Coward, J. I. G., & Schloss, J. M. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02874-4 · Cited by 7
Single-Cell Image-Based Analysis Reveals Chromatin Changes during the Acquisition of Tamoxifen Drug Resistance
Zhao, H., Lin, L. F., Hahn, J., Xie, J., Holman, H. F., & Yuan, C. (2022) · Life · doi:10.3390/life12030438 · Cited by 6
Epigenetic Regulation Towards Acquired Drug Resistance in Cancer
Ketkar, M., & Dutt, S. (2022) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-3-031-07634-3_14 · Cited by 7
Differential Regulation of Methylation-Regulating Enzymes by Senescent Stromal Cells Drives Colorectal Cancer Cell Response to DNA-Demethylating Epi-Drugs
Agrawal, K., Das, V., Kudlová, N., Gurský, J., Džubák, P., & Hajdúch, M. (2018) · Stem Cells International · doi:10.1155/2018/6013728 · Cited by 7
First-Line Combination Treatment with Low-Dose Bipolar Drugs for ABCB1-Overexpressing Drug-Resistant Cancer Populations
Yoon, S., & Kim, H. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098389 · Cited by 6
A comparison of mutation and amplification-driven resistance mechanisms and their impacts on tumor recurrence
Li, A., Kibby, D., & Foo, J. (2023) · Journal of Mathematical Biology · doi:10.1007/s00285-023-01992-8 · Cited by 6
Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
George, J., Chen, Y., Abdelfattah, N., Yamamoto, K., Gallup, T. D., Adamson, S. I., Rybinski, B., Srivastava, A., Kumar, P., Lee, M. G., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0124 · Cited by 6
Epigenetic Biomarkers of Disease
Voyias, P. D., Patel, A. J., & Arasaradnam, R. P. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00010-7 · Cited by 6
Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial complex II and affecting OXPHOS
Niu, L., Kang, X., Zheng, J., Wu, F., Liu, S., Liu, H., Liu, H., Wang, J., Fan, D., Nie, Y., et al. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107996 · Cited by 5
Gastrointestinal cancer cells with Pt-resistance and relationship with aberrant expression of long non-coding RNAs
Ferretti, V., Klugh, K. L., Doucette, K. K., Crans, D. C., & León, I. E. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215791 · Cited by 5
Epigenetic regulation of cancer
Galluzzi, L., & Spada, S. (2025) · International review of cytology · doi:10.1016/s1937-6448(25)00015-2 · Cited by 6
Optimal dosing of anti-cancer treatment under drug-induced plasticity
Gunnarsson, E. B., Magnússon, B. V., & Foo, J. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00571-5 · Cited by 6
Molecular Determinants of Chemotherapy Resistance in Ovarian Cancer
Cooley, M., Fang, P., Fang, F., Nephew, K. P., & CHIEN, J. R. (2015) · Pharmacogenomics · doi:10.2217/pgs.15.130 · Cited by 5
Deubiquitinating enzyme inhibitor alleviates cyclin A1‐mediated proteasome inhibitor tolerance in mixed‐lineage leukemia
Ge, M., Xu, Q., Kang, T., Li, D., Wang, R., Chen, Z., Xie, S., Wang, W., & Liu, H. (2021) · Cancer Science · doi:10.1111/cas.14892 · Cited by 5
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab-resistant HER2-positive breast cancerPreprint
Hua, Y., Duan, N., Sun, C., Yang, F., Tian, M., Sun, Y., Zhao, S., Gong, J., Liu, Q., Huang, X., et al. (2025) · eLife · doi:10.7554/elife.103953 · Cited by 5
The DMRTA1-SOX2 positive feedback loop promotes progression and chemotherapy resistance of esophageal squamous cell carcinoma
ZHANG, R., Zhou, P., OU, X., ZHAO, P., GUO, X., Xi, M., & QING, C. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.030184 · Cited by 4
A comprehension of signaling pathways and drug resistance; an insight into the correlation between microRNAs and cancer
Alsaab, H. O., Abdullaev, B., Alkhafaji, A. T., Alawadi, A. H., Jahlan, I. O., Bahir, H., Bisht, Y. S., Alsaalamy, A. H., jabbar, A. M., & Mustafa, Y. F. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154848 · Cited by 4
DNA Methylation as Drug Sensitivity Marker in RCC: A Systematic Review
Koudonas, A., Dimitriadis, G., Anastasiadis, A., & Papaioannou, M. (2024) · Epigenomes · doi:10.3390/epigenomes8030028 · Cited by 4
A Model of Butyrate Activity and Resistance in CRC
Bordonaro, M. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70656 · Cited by 4
Hypothesis: Sam68 and Pygo2 mediate cell type-specific effects of the modulation of CBP-Wnt and p300-Wnt activities in Colorectal Cancer Cells
Bordonaro, M. (2021) · Journal of Cancer · doi:10.7150/jca.59726 · Cited by 4
Epigenetic Modulators
Duncan, K. W., & Campbell, J. E. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_30 · Cited by 4
Glioblastoma recurrence and the role of MGMT promoter methylationPreprint
Storey, K., Leder, K., Hawkins-Daarud, A. J., Swanson, K. R., Ahmed, A. U., Rockne, R. C., & Foo, J. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/317636 · Cited by 4
Discovery of a novel benzofuran-7-carboxamide-based PARP1/c-Met dual inhibitor for addressing c-Met amplification-mediated PARP1i acquired-resistance
Sun, Z., Hu, M., Xu, J., Zhai, B., Zhang, Y., Zhang, W., Wang, B., Wang, R., Hu, Z., Xu, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118164 · Cited by 3
Reinforcement learning-based design of sequential drug treatment targeting the evolving tumour landscape with SequenTx
Chen, X., Deng, Y. C., Yang, X., Zhang, Y., Huang, Y., Li, S., Yang, H., Shi, Q., Wu, S., Chen, S., et al. (2026) · Nature Machine Intelligence · doi:10.1038/s42256-026-01192-1 · Cited by 3
554 Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells
Brown, R. E., Fuchter, M., Curry, E. W., Green, I. A., Kandil, S., Cherblanc, F., Payne, L., Chapman‐Rothe, N., Shamsaei, E., Srimongkolpithak, N., et al. (2014) · European Journal of Cancer · doi:10.1016/s0959-8049(14)70680-x · Cited by 3
Self-citation
Drug resistance in gynecologic cancers: Findings and underlying mechanisms
Acharya, L., Mani, H., Ullah, A., Hussain, S., Ali, S., & Ahmad, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824299-5.00007-1 · Cited by 3
Functionalized Lineage Tracing Can Enable the Development of Homogenization-Based Therapeutic Strategies in Cancer
Gutierrez, C., Vilas, C. K., Wu, C. J., & Al’Khafaji, A. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859032 · Cited by 3
Existence, stability, and numerical simulation of a nonlinear brain tumor model
Afshari, H., Kalantari, S., Anvari, M., & Marasi, H. R. (2025) · Journal of Inequalities and Applications · doi:10.1186/s13660-025-03276-9 · Cited by 3
Paclitaxel in breast cancer – drug resistance and strategies to counteract it
Zajdel, A., Wolny, D., Kałucka-Janik, M., & Wilczok, A. (2019) · Postępy Higieny i Medycyny Doświadczalnej · doi:10.5604/01.3001.0013.5251 · Cited by 3
Developing Enzyme‐Responsive Nanomedicine for Inhibition of hTERT Mitochondrial Translocation
Qin, H., Yan, Z., Du, Z., Ren, J., & Qu, X. (2020) · Advanced Therapeutics · doi:10.1002/adtp.201900203 · Cited by 3
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2024) · International review of cytology · doi:10.1016/s1937-6448(24)00113-8 · Cited by 2
Low-Dose Perifosine, a Phase II Phospholipid Akt Inhibitor, Selectively Sensitizes Drug-Resistant ABCB1-Overexpressing Cancer Cells
Park, J. H., Lee, H., Zheng, T., Shin, J. K., Yoon, S., & Kim, H. S. (2024) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2024.069 · Cited by 2
High Mobility Group A1 Chromatin Keys: Unlocking the Genome During MPN Progression
Resar, L. M. S., & Luo, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26052125 · Cited by 2
PDX ou xénogreffe dérivée de la tumeur du patient, la renaissance d’un modèle oublié : son implication dans la recherche et la clinique de demain
Surdez, D., & Daudigeos‐Dubus, E. (2016) · Revue d Oncologie Hématologie Pédiatrique · doi:10.1016/j.oncohp.2016.10.017 · Cited by 2
Mechanisms of resistance to a PI3K inhibitor in gastrointestinal stromal tumors: an omic approach to identify novel druggable targets
Ravegnini, G., Sammarini, G., Morán, S., Calice, G., Indio, V., Urbini, M., Astolfi, A., Zanotti, F., Pantaleo, M. A., Hrelia, P., et al. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189661 · Cited by 4
Identification of Phospho-Tyrosine Targets as a Strategy for the Treatment of Esophageal Adenocarcinoma Cells
Lee, J., Chen, R., Mohanakumar, T., Bremner, R. M., Mittal, S. K., & Fleming, T. P. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s309388 · Cited by 2
Mitochondrial fission promotes self-renewal and tumorigenic potential in prostate cancer
Civenni, G., Carbone, G. M., & Catapano, C. V. (2019) · Molecular & Cellular Oncology · doi:10.1080/23723556.2019.1644598 · Cited by 2
G-quadruplex structures regulate long-range transcriptional reprogramming to promote drug resistance in ovarian cancerPreprint
Robinson, J., Flint, G., Garner, I., Galli, S., Maher, T. E., Kuimova, M. K., Vilar, R., McNeish, I. A., Brown, R. E., Keun, H. C., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.06.24.600010 · Cited by 3
Self-citation
Detection of metabolic adaptation in a triple-negative breast cancer animal model with [18F]choline-PET imaging as a surrogate for drug resistance
Kohan, A. A., Lupien, M., Cescon, D. W., Deblois, G., Ventura, M., Metser, U., & Veit‐Haibach, P. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06546-0 · Cited by 1
Optimal control in reducing side effects during and after chemotherapy of solid tumors
Joorsara, Z., Hosseini, S. M., & Esmaili, S. (2024) · Mathematical Methods in the Applied Sciences · doi:10.1002/mma.10049 · Cited by 1
Star wars against leukemia: attacking the clones
Toma, M. M., & Skórski, T. (2024) · Leukemia · doi:10.1038/s41375-024-02369-6 · Cited by 3
MemorySeq identifies heritable epigenetic phenotypes that initiate cell culture stress tolerance in CHO cells
Grissom, S., Dixon, Z., Singh, A., & Blenner, M. (2025) · iScience · doi:10.1016/j.isci.2025.113478 · Cited by 1
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2026) · International review of cytology · doi:10.1016/s1937-6448(26)00028-6 · Cited by 1
MYC Addiction as a Targetable Vulnerability in Nelarabine‐Resistant T‐Cell Acute Lymphoblastic Leukemia
Gao, J., Lin, C., Chen, S., Mo, Q., Bao, C., Deng, H., Chen, Z., Hao, W., Zhang, L., & Wei, M. (2026) · Cancer Science · doi:10.1111/cas.70382 · Cited by 1
Synergistic combination of YS-1 and adriamycin inhibits human renal cancer through ERK1/2 signaling pathway in vitro and in vivo
Yu, X., Yang, Q., Lin, S., Yuan, S., & Sun, L. (2017) · Oncology Reports · doi:10.3892/or.2017.5373 · Cited by 1
Mathematical modeling of drug resistance in heterogeneous cancer cell populations
Bao, K., Liang, G., Tian, T., & Zhang, X. (2023) · International Journal of Biomathematics · doi:10.1142/s1793524523501012 · Cited by 1
Combating the Epigenome: Elucidation of Mechanisms Underlying Chemoresistance and Enhancing Tumor Immunogenicity
Çaçan, E. (2022) · Digital Archive @ GSU · doi:10.57709/7305124 · Cited by 1
Signal Transduction in Disease
Ganey, P. E., & Misek, S. A. (2019) · Wiley eBooks · doi:10.1002/9781119060208.ch4 · Cited by 1
Population Dynamics of Hybrid State during Adaptive Therapy in CancerPreprint
Singh, G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.11.27.470219 · Cited by 1
Grainyhead-like-2 inhibits the co-activator p300, suppressing tubulogenesis and the epithelial-mesenchymal transition
Pifer, P. M. (2016) · The Research Repository @ WVU (West Virginia University) · doi:10.33915/etd.6420
Mediator Kinase Inhibition Impedes Transcriptional Plasticity and Prevents Resistance to ERK/MAPK-Targeted Therapy in KRAS -Mutant CancersPreprint
Nussbaum, D. P., Martz, C. A., Waters, A. M., Barrera, A., Rutter, J. C., Cerda-Smith, C. G., Stewart, A. E., Wu, C., Çakır, M., Levandowski, C. B., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.17.508384 · Cited by 1
Multi‐Drug Resistance in Cancer
Malviya, R., Singh, A. K., & Yadav, D. (2023) · Wiley eBooks · doi:10.1002/9781394209866.ch1 · Cited by 1
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancerPreprint
Hua, Y., Duan, N., Sun, C., Yang, F., Tian, M., Sun, Y., Zhao, S., Gong, J., Liu, Q., Huang, X., et al. (2025) · eLife · doi:10.7554/elife.103953.2 · Cited by 1
Histone Posttranslational Modifications in Breast Cancer and Their Use in Clinical Diagnosis and Prognosis
Magnani, L., Louloupi, A., & Zwart, W. T. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801899-6.00023-1
Self-citation
Diversity and implication of MAPK signal transduction involved in the regulation of chemotherapy-induced DNA damage response
Alaoui‐Jamali, M. A., Wurzba, S. D., & Bijian, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803582-5.00010-3
Epigenetic Alterations in Endocrine-Dependent Cancers: Implications of Endocrine Dysfunctions
Deblois, G., & Lupien, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803239-8.00020-x
Cubic and spherical nanoparticles for detection and therapy of cancer
Suresh, D. (2016) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/62484
What Is Epigenetics?
Chiang, T.-C., & Su, L. J. (2015) · Molecular and integrative toxicology · doi:10.1007/978-1-4471-6678-8_1
Clinical Observation of Improved Outcomes of Patients With BRCA 1/2 Breast Cancer Treated With Everolimus Prior to DNA-Damaging Therapy
Anderson, M., Denson, A. C., Zaman, S., Han, H. S., & Soliman, H. H. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00123
Multiscale Stochastic Modeling Connects Cancer Drug Resistance Mechanisms to Population Survival Rates
Sun, X. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76185
The Role of Inter-Alpha-Trypsin-Inhibitor-Heavy-Chain-5 (ITIH5) in Suppressing Pancreatic Cancer Metastasis
Young, E. D. (2018) · KU ScholarWorks (University of Kansas)
Therapeutic Potential of Pharmacoepigenetics in Cholangiocarcinoma
O’Rourke, C. J., Satriano, L., Oliveira, D. V. N. P., Muñoz-Garrido, P., & Andersen, J. B. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813939-4.00017-6
Phenotypic analysis of an MLL-AF4 gene regulatory network reveals indirect CASP9 repression as a mode of inducing apoptosis resistancePreprint
Harman, J. R., Thorne, R., Jamilly, M., Tapia, M. C., Crump, N. T., Rice, S., Beveridge, R. D. D., Morrissey, E. R., Bruijn, M. F. T. R. D., Roberts, I. A. G., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.30.179796
Therapeutic Epigenetics- A Boon to the Future
Dhas, D. B. B. (2016) · Annals of SBV · doi:10.5005/jp-journals-10085-5106
Bioavailability and Modes of Action of Novel Metal Based Phenanthroline Drugs
O’Leary, T. (2021) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/7sw6-vk06
Synthetic Technology of Noncoding RNAs Used in Bone Disease Research and Therapeutics
Tian, Y. E., Yin, C., Yang, C., Ji, M., Chu, X., & Qian, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-2402-5_7
Translocation of Intracellular CD24 Towards Cell Membrane Constitutes a Triggering Event for Drug Resistance in Breast Tumor Cell: Correlation With Dynamics of p38MAPK ActivationPreprint
Huth, H. W., Goes, A. M., & Ropert, C. (2020) · doi:10.21203/rs.3.rs-109614/v1
Exploring epigenetic mechanisms to target mammary cancer cells: a comparative approach
Xavier, P. L. P. (2020) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.74.2020.tde-06052021-153621
Epigenetic biomarkers of disease
Cháves, P., Onieva, J. L., & Barragán, I. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-823928-5.00037-2
Faculty Opinions recommendation of TRAIL-induced variation of cell signaling states provides nonheritable resistance to apoptosis.
Clairambault, J. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736873710.793575390
Data from Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells
El-Kenawi, A., Berglund, A., Estrella, V. C., Zhang, Y., Liu, M., Putney, R. M., Yoder, S., Johnson, J., Brown, J. S., & Gatenby, R. A. (2023) · doi:10.1158/0008-5472.c.6514344.v1
Data from Cancer Stem Cells, not Bulk Tumor Cells, Determine Mechanisms of Resistance to SMO Inhibitors
George, J., Chen, Y., Abdelfattah, N., Yamamoto, K., Gallup, T. D., Adamson, S. I., Rybinski, B., Srivastava, A., Kumar, P., Lee, M. G., et al. (2023) · doi:10.1158/2767-9764.c.6550640.v1
Erastin plus Tubacin Treatment Promotes Breast Cancer Cell Death of HCC38
吴, 灿. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1351221
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2023) · International review of cytology · doi:10.1016/s1937-6448(23)00145-4
Epigenetic regulation of cancer
Spada, S., & Galluzzi, L. (2024) · International review of cytology · doi:10.1016/s1937-6448(24)00026-1
Recently Emerging Liquid Biopsy-based Non-invasive Methylation Biomarkers for Gastric Cancer Diagnosis, Prognosis and Therapy Response Prediction
Alom, S., Anal, B. V., & Ghosh, S. (2024) · Current Cancer Therapy Reviews · doi:10.2174/0115733947313656240819093316
Targeting SLC7A11-mediated cysteine metabolism for the treatment of trastuzumab resistant HER2 positive breast cancerPreprint
Hua, Y., Duan, N., Sun, C., Yang, F., Tian, M., Sun, Y., Zhao, S., Gong, J., Liu, Q., Huang, X., et al. (2025) · eLife · doi:10.7554/elife.103953.1
Additional file 2 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y., Teicher, B. A., & Krushkal, J. (2021) · Figshare · doi:10.6084/m9.figshare.14176027
Additional file 21 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y., Teicher, B. A., & Krushkal, J. (2021) · Figshare · doi:10.6084/m9.figshare.14176024
Additional file 1 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y., Teicher, B. A., & Krushkal, J. (2021) · Figshare · doi:10.6084/m9.figshare.14176018
Additional file 16 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y., Teicher, B. A., & Krushkal, J. (2021) · Figshare · doi:10.6084/m9.figshare.14176006
Additional file 20 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y., Teicher, B. A., & Krushkal, J. (2021) · Figshare · doi:10.6084/m9.figshare.14176021
Additional file 1 of Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance
Gallon, J., Loomis, E. W., Curry, E., Martin, N., Brody, L., Garner, I., Brown, R., & Flanagan, J. M. (2021) · Figshare · doi:10.6084/m9.figshare.14738840
Self-citation
Additional file 19 of Association of expression of epigenetic molecular factors with DNA methylation and sensitivity to chemotherapeutic agents in cancer cell lines
Vural, S., Palmisano, A., Reinhold, W. C., Pommier, Y., Teicher, B. A., & Krushkal, J. (2021) · Figshare · doi:10.6084/m9.figshare.14176015
A proteomic approach for understanding the metabolic adaptations in non-small cell lung cancer
Martín-Bernabé, A. (2018) · theses.fr (ABES) · doi:10.70675/426e7b40z057az4326z8cfez7da3a5c12c7e
Non-genetic regulation of chemopersistence in Triple Negative Breast Cancers
Baudre, L. (2024) · theses.fr (ABES) · doi:10.70675/6422f0bbza832z4dcfza920zaa55605f8a31
Cisplatin-Induced Plasticity Drives Cross-Resistance to CDK4/6 Inhibitors and Reveals Targetable Vulnerabilities Through HDAC Inhibition in Esophageal Squamous Cell CarcinomaPreprint
Ávalos-Moreno, M., Vigato, A., Moresi, F., Japon-Ruiz, D., Beck, B., & Bisteau, X. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.17.738886

Authors: Brown, R., Curry, E., Magnani, L., Wilhelm-Benartzi, C. S., & Borley, J.
Affiliations: Hammersmith Hospital (GB)
Corresponding author: Brown, Robert
ORCID: Brown, Robert
Curry, Edward
Magnani, Luca
Wilhelm-Benartzi, Charlotte S.
Venue: Nature Reviews Cancer
Publisher: Springer Science and Business Media LLC
Published: 2014-09-25
Volume: 14
Issue: 11
Pages: 747-753
ISSN: 1474-175X (ISSN-L)
1474-1768
DOI: 10.1038/nrc3819
OpenAlex: W2095124748
Cited by: 301
References: 96
Citations by year: 2026: 4 · 2025: 16 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 41 · 2020: 37 · 2019: 34 · 2018: 27 · 2017: 23 · 2016: 30 · 2015: 18 · 2014: 1
FWCI: 2.29
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature reviews. Cancer (publishedVersion)
PubMed (publishedVersion)
ORCA Online Research @Cardiff (Cardiff University) (submittedVersion)
Funders: Cancer Research UK (13086, A13086, 15954)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords: epigenetic heterogeneity, acquired drug resistance, cancer, epigenetic targeting, chemoresistance, gene expression evolution
MeSH terms: Animals, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm, Epigenesis, Genetic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Poised epigenetic states and acquired drug resistance in cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks